Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
50.31 USD -6.40% Intraday chart for Apogee Therapeutics, Inc. -5.47% +80.06%
05-15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI
05-13 Apogee Therapeutics' Q1 Net Loss Widens MT

Evolution of the average Target Price on Apogee Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9014aa28ede516df492e9e5691eaaec8.31YFDcMHmBxqEWSw7oJ7NVvbcNf2wvjCKWsnICiLLvA.rRFRf6B-oSonelbpmNsaZHaLBpiTmLq6TlgTVHLvT5u5P0FbgmrpLAVUUA~ec2f770e70d6d8032d987bd74c71cc0d

Analyst Recommendations on Apogee Therapeutics, Inc.

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43 MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
50.31 USD
Average target price
84.83 USD
Spread / Average Target
+68.62%
High Price Target
95 USD
Spread / Highest target
+88.83%
Low Price Target
75 USD
Spread / Lowest Target
+49.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apogee Therapeutics, Inc.

BofA Securities
Jefferies & Co.
Wedbush
Guggenheim
BTIG
TD Cowen
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APGE Stock
  4. Consensus Apogee Therapeutics, Inc.